Sign in to continue:

Sunday, March 1st, 2026

ZTO Express Announces Board Meeting and Earnings Release Schedule for Q4 and Full Year 2025 Results




ZTO Express Announces Board Meeting and Key Financial Events

ZTO Express (Cayman) Inc. Schedules Board Meeting to Approve Q4 and Annual 2025 Financial Results; Earnings Call Details Released

Key Highlights for Investors

  • Board Meeting Scheduled: ZTO Express (Cayman) Inc. (“ZTO Express”) will hold a board meeting on Tuesday, March 17, 2026 (Beijing time).
  • Approval of Financial Results: The Board will review and approve the company’s unaudited financial results for the fourth quarter ended December 31, 2025, and the unaudited annual results for the fiscal year ended December 31, 2025.
  • Potential Dividend Declaration: The Board will also consider the declaration and payment of a dividend, if any. This is of significant interest to shareholders as dividend policy directly impacts shareholder returns and could influence the share price.
  • Results Announcement: The unaudited results will be released on Wednesday, March 18, 2026 (Beijing time), before the trading hours of The Stock Exchange of Hong Kong Limited.
  • Earnings Conference Call: Management will host an earnings call at 8:30 A.M. Beijing time (March 18, 2026), which corresponds to 8:30 P.M. U.S. Eastern Time on March 17, 2026.
  • Call-In Details Provided: Investors can join the conference call through multiple regional dial-in numbers with the provided passcode (5925555).
    • United States/Canada: 1-888-317-6003
    • Hong Kong: 800-963976
    • Mainland China: 4001-206115
    • International: 1-412-317-6061
    • Passcode: 5925555
  • Replay and Webcast: A replay will be accessible until Tuesday, March 24, 2026 via:
    • United States/Canada: 1-855-669-9658
    • International: 1-412-317-0088
    • Passcode: 7894484

    Additionally, a live and archived webcast will be available on the company’s investor relations website: http://zto.investorroom.com

  • Board Composition: As of February 27, 2026, the Board is chaired by Mr. Meisong LAI, with a mix of executive, non-executive, and independent non-executive directors, ensuring diverse oversight and governance.

Important Information for Shareholders

  • Weighted Voting Rights Structure: ZTO Express features a weighted voting rights structure where Class A ordinary shares have one vote each, while Class B ordinary shares have ten votes each. This structure may affect corporate control and is a key consideration for investors assessing their influence on company decisions.
  • Potentially Price Sensitive Events:
    • The release of Q4 and annual 2025 financial results may significantly impact the share price, depending on performance versus market expectations.
    • The consideration and possible declaration of a dividend is a noteworthy event. Any dividend announcement or changes to dividend policy can have a direct effect on share value and investor sentiment.
  • Transparency and Accessibility: The company’s commitment to transparency is underlined by the scheduled webcast and replay options, ensuring all investors have access to management’s commentary and the opportunity to ask questions.

Conclusion

The upcoming board meeting and subsequent release of financial results, along with the potential dividend declaration, are highly significant events for ZTO Express shareholders and prospective investors. These announcements provide crucial insights into the company’s operational performance, financial health, and future outlook. Investors are encouraged to participate in the earnings call or access the webcast for the latest updates and management’s strategic commentary.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a professional advisor before making investment decisions. The information provided is based on the company’s public announcement and is subject to change without notice.




View ZTO EXPRESS-W Historical chart here



Hangzhou Jiuyuan Genetic Biopharmaceutical’s Jikeqin Biosimilar Semaglutide Marketing Application Approved by NMPA for Weight Management 1

Hangzhou Jiuyuan Genetic Biopharmaceutical: Jikeqin® Marketing Application Approved by NMPA Hangzhou Jiuyuan Genetic Biopharmaceutical Announces Key Milestone for Jikeqin® Marketing Application for Biosimilar GLP-1 Receptor Agonist Accepted by NMPA Hangzhou Jiuyuan Genetic Biopharmaceutical Co.,...

Li Auto Inc. Announces Board Meeting and Earnings Conference Call for Q4 and Annual 2025 Financial Results

Li Auto Inc. Announces Board Meeting and Earnings Release Date Li Auto Inc. Schedules Key Board Meeting and Earnings Release for Q4 and Full Year 2025 Li Auto Inc. (HKEX: 2015), a leading Chinese...

Disclosure of Share Dealings by Morgan Stanley in Bright Smart Securities & Commodities Group Limited – February 2026

Details of the Dealings Morgan Stanley & Co., International plc, a Class (5) associate connected with the Offeror, conducted the following dealings on 25 February 2026: Purchase of Shares: Nature: Hedging of Delta 1...

   Ad